文献速递心力衰竭与心肌病

靶向microRNA-132的反义疗法在心力衰竭患者中的首次人体1b期随机双盲安慰剂对照研究

Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.
PubMed 文献 · Eur Heart J · 2021-01-01

CDR132L是一种靶向miR-132的反义寡核苷酸,在临床前模型中可减轻甚至逆转心衰。CDR132L安全耐受,无剂量限制性毒性,剂量依赖性地持续降低血浆miR-132,≥1 mg/kg组NT-proBNP中位降低23.3%,对照组中位升高0.9%,并观察到QRS波窄化及心脏纤维化生物标志物的积极趋势。

要点

  • CDR132L在慢性缺血性心衰患者中安全耐受,未见剂量限制性毒性。
  • CDR132L剂量依赖性地持续降低血浆miR-132,有效剂量水平建议≥1 mg/kg。
  • ≥1 mg/kg CDR132L组NT-proBNP中位降低23.3%,对照组中位升高0.9%。

核心结论

  • CDR132L是首个在心力衰竭患者中开展临床试验的反义药物,安全耐受,证实线性血浆药代动力学且无蓄积迹象,并提示心脏功能改善。
  • 尽管研究受小样本量限制,但该药提示的疗效非常鼓舞人心,值得开展进一步临床研究以确认CDR132L对心衰治疗的有益药效学效应。

研究设计与样本

  • 随机、安慰剂对照、双盲、剂量递增的1b期临床研究(NCT04045405),评估CDR132L在慢性缺血性心衰标准治疗患者中的安全性、药代动力学、靶点结合及探索性药效学效应。
  • 纳入左心室射血分数≥30%且<50%或筛选时NT-proBNP>125 ng/L的患者。

主要发现

  • CDR132L安全且耐受良好,无明显的剂量限制性毒性。
  • 药代动力学/药效学剂量建模方法提示有效剂量水平为≥1 mg/kg CDR132L。
  • CDR132L治疗导致血浆miR-132呈剂量依赖性、持续性降低。
  • 接受CDR132L≥1 mg/kg的患者NT-proBNP中位降低23.3%,而对照组中位升高0.9%。
  • CDR132L治疗诱导显著的QRS波窄化,并在相关心脏纤维化生物标志物方面呈现令人鼓舞的积极趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Cardiac microRNA-132-3p (miR-132) levels are increased in patients with heart failure (HF) and mechanistically drive cardiac remodelling processes. CDR132L, a specific antisense oligonucleotide, is a first-in-class miR-132 inhibitor that attenuates and even reverses HF in preclinical models. The aim of the current clinical Phase 1b study was to assess safety, pharmacokinetics, target engagement, and exploratory pharmacodynamic effects of CDR132L in patients on standard-of-care therapy for chronic ischaemic HF in a randomized, placebo-controlled, double-blind, dose-escalation study (NCT04045405). METHODS AND RESULTS: Patients had left ventricular ejection fraction between ≥30% and <50% or amino terminal fragment of pro-brain natriuretic peptide (NT-proBNP) >125 ng/L at screening. Twenty-eight patients were randomized to receive CDR132L (0.32, 1, 3, and 10 mg/kg body weight) or placebo (0.9% saline) in two intravenous infusions, 4 weeks apart in four cohorts of seven (five verum and two placebo) patients each. CDR132L was safe and well tolerated, without apparent dose-limiting toxicity. A pharmacokinetic/pharmacodynamic dose modelling approach suggested an effective dose level at ≥1 mg/kg CDR132L. CDR132L treatment resulted in a dose-dependent, sustained miR-132 reduction in plasma. Patients given CDR132L ≥1 mg/kg displayed a median 23.3% NT-proBNP reduction, vs. a 0.9% median increase in the control group. CDR132L treatment induced significant QRS narrowing and encouraging positive trends for relevant cardiac fibrosis biomarkers. CONCLUSION: This study is the first clinical trial of an antisense drug in HF patients. CDR132L was safe and well tolerated, confirmed linear plasma pharmacokinetics with no signs of accumulation, and suggests cardiac functional improvements. Although this study is limited by the small patient numbers, the indicative efficacy of this drug is very encouraging justifying additional clinical studies to confirm the beneficial CDR132L pharmacodynamic effects for the treatment of HF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Täubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021. PMID: 33245749. doi:10.1093/eurheartj/ehaa898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。